Thorsten Kirschberg
Corporate Officer/Principal bei BIOMEA FUSION, INC.
Ursprung des Netzwerks ersten Grades von Thorsten Kirschberg
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 21 | |
| Public Company | Biotechnology | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Thorsten Kirschberg
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Compliance Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Comptroller/Controller/Auditor Investor Relations Contact Director/Board Member | |
| ARROWHEAD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| AMARIN CORPORATION PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
OrbiMed Advisors LLC
 OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Investment Managers | Founder Corporate Officer/Principal | |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
3-Dimensional Pharmaceuticals, Inc.
 3-Dimensional Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology 3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases | Pharmaceuticals: Major | Director/Board Member | |
Aisling Capital LLC
 Aisling Capital LLC Investment ManagersFinance Aisling Capital LLC (Aisling Capital) is an venture capital firm founded in 1999 by Dennis Joseph Purcell. The firm is headquartered in New York, New York. | Investment Managers | Private Equity Investor | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
Crown Bioscience, Inc.
 Crown Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| TURG POIN | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Neuberger Berman BD LLC
 Neuberger Berman BD LLC Investment ManagersFinance Neuberger Berman BD LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. It is directly owned by Neuberger Berman Investment Advisers LLC, which is an indirect, wholly-owned subsidiary of Neuberger Berman Group LLC, which is owned by NBSH Acquisition LLC. The firm traces their origin back to the 1939 founding of Neuberger & Berman, its predecessor firm. In 1950, Neuberger Berman became one of the first firms to offer a no-load mutual fund to individual investors. Neuberger Berman BD manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. | Investment Managers | Analyst-Equity | |
| University of California, Los Angeles | College/University | Doctorate Degree Masters Business Admin | |
Amarin Pharmaceuticals, Inc.
 Amarin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Bausch Health Cos., Inc., Amarin Pharmaceuticals, Inc. is a pharmaceutical company that manufactures and develops pharmaceuticals. The company is based in Mill Valley, CA. | Pharmaceuticals: Major | Director/Board Member | |
| Auburn University | College/University | Undergraduate Degree | |
| University of California, Riverside | College/University | Graduate Degree | |
Council on Foreign Relations, Inc.
 Council on Foreign Relations, Inc. Investment Trusts/Mutual FundsMiscellaneous Council on Foreign Relations, Inc. provides and disseminates ideas on foreign policies to individuals, corporate members, journalists and policy makers. It operates a forum for government officials, students and other interested parties to study and discuss world issues and impact on American foreign policies. The company publishes Foreign Affairs, a magazine that comes out six times a year, along with books and studies by its own scholars. Council on Foreign Relations was founded in 1921 and is headquartered in New York City, NY. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Harvard Medical School | College/University | Doctorate Degree | |
| United Properties Immobilien & Anlagen GmbH | Chief Executive Officer | ||
| KITE PHARMA INC | Biotechnology | Chief Tech/Sci/R&D Officer | |
Sabby Capital LLC
 Sabby Capital LLC Investment ManagersFinance Sabby Capital LLC is an independent hedge fund manager headquartered in Upper Saddle River, New Jersey. The firm was founded by Hal D. Mintz in 2011. Sabby Capital manages multiple private investment funds for high net worth investors. | Investment Managers | Analyst-Equity | |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Pharmaceuticals: Major | Director/Board Member | |
| Tufts University School of Medicine | College/University | Corporate Officer/Principal | |
Point Sur Investors LLC
 Point Sur Investors LLC Investment ManagersFinance Point Sur Investors LLC provides investment advice. The private company is based in El Cerrito, CA and has subsidiaries in the United States. The company was founded in 2015 by Thomas Butler, Rainer M. Erdtmann. | Investment Managers | Founder Founder | |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | Biotechnology | Director/Board Member | |
| SUMMIT THERAPEUTICS INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Philadelphia Ventures, Inc.
 Philadelphia Ventures, Inc. Investment ManagersFinance Philadelphia Ventures Inc (Philadelphia Ventures) was a venture capital firm founded in 1967 by Norley Michael. The firm was headquartered in Philadelphia, Pennsylvania. | Investment Managers | Corporate Officer/Principal | |
| EIDOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Director/Board Member | |
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Geneception, Inc.
 Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Pins Medical, Inc. | Director/Board Member | ||
Garuda Therapeutics, Inc.
 Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
Ablaze Pharmaceuticals
 Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
Avistone Pharmaceuticals
 Avistone Pharmaceuticals BiotechnologyHealth Technology Avistone Pharmaceuticals is a Chinese clinical-stage biotechnology company that specializes in precision oncology therapeutics. The company is located in China. | Biotechnology | Director/Board Member | |
Shanghai Rarestone Health Tech Group Co. Ltd.
 Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | Pharmaceuticals: Major | Director/Board Member | |
| BIOHAVEN LTD. | Pharmaceuticals: Major | Director/Board Member | |
RiboX Therapeutics, Inc.
 RiboX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology RiboX Therapeutics, Inc. engages in the development of fully engineered circular RNA therapeutics. The private company is based in Shanghai, China. | Pharmaceuticals: Major | Director/Board Member | |
Pharmacyclics, Inc.
 Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Pharmaceuticals: Major | Compliance Officer Chief Tech/Sci/R&D Officer Comptroller/Controller/Auditor Chief Tech/Sci/R&D Officer | |
Zenas Pharma, Inc.
 Zenas Pharma, Inc. BiotechnologyHealth Technology Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. | Biotechnology | Director/Board Member | |
Visirna Therapeutics, Inc.
 Visirna Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Visirna Therapeutics, Inc. manufactures and commercializes RNAi-based investigational cardiometabolic medicines. The company is based in Shanghai, China. | Pharmaceuticals: Other | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 39 |
| China | 7 |
| Irland | 2 |
| Mexiko | 2 |
| Deutschland | 2 |
Sektoral
| Health Technology | 33 |
| Finance | 9 |
| Consumer Services | 6 |
| Commercial Services | 2 |
| Miscellaneous | 2 |
Operativ
| Director/Board Member | 124 |
| Corporate Officer/Principal | 50 |
| Independent Dir/Board Member | 42 |
| Chief Tech/Sci/R&D Officer | 21 |
| Undergraduate Degree | 16 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Carl Gordon | 59 |
| Bihua Chen | 32 |
| Eric Aguiar | 29 |
| Hong Bo Lu | 28 |
| Ramses Erdtmann | 13 |
| Elizabeth Faust | 12 |
| Sumita Ray | 12 |
| Sunny Lee Ryan | 10 |
| Heow Tan | 9 |
| Mark Vignola | 9 |
| Franco Valle | 7 |
| Senthil Sundaram | 7 |
| Juan Frias | 6 |
| Randall L. Halcomb | 6 |
| Tom Butler | 6 |
- Börse
- Insiders
- Thorsten Kirschberg
- Unternehmensverbindungen